Patents by Inventor Kunwar Shailubhai

Kunwar Shailubhai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220332822
    Abstract: This invention provides methods of subcutaneous administration of anti-CD3 monoclonal antibodies (mAbs) either alone or in combination with monoclonal antibodies, that recognize the Interleukin-6 (IL-6) and IL-6 receptor (IL-6R) complex for the treatment, prevention or alleviating a symptom of a disease.
    Type: Application
    Filed: April 18, 2022
    Publication date: October 20, 2022
    Inventors: Kunwar SHAILUBHAI, Vaseem A. PALEJWALA, Jules S. JACOB
  • Publication number: 20220281915
    Abstract: The present disclosure relates to, among other things, compositions and methods for treating pain such as neuropathic pain, ocular pain, chronic pain, pain resulting from chemotherapy or radiation, and pain resulting from nerve injury or nerve degeneration. In some embodiments, the pain can be resulting from an inflammatory condition, dysesthesia, or allodynia. The present disclosure also relates to methods for treating an inflammatory condition such as ocular inflammation, retinal inflammation, dry eye, uveitis, allergic conjunctivitis, and inflammation resulting from nerve injury or nerve degeneration.
    Type: Application
    Filed: July 29, 2020
    Publication date: September 8, 2022
    Applicant: OKYO Pharma Limited
    Inventors: Kunwar SHAILUBHAI, Rajkumar V. PATIL
  • Publication number: 20220267377
    Abstract: The present disclosure relates to peptide compositions and methods for treating an inflammatory condition such as ocular inflammation, retinal inflammation, dry eye, uveitis, allergic conjunctivitis, and inflammation resulting from nerve injury or nerve degeneration. The peptide compositions disclosed herein can also be used for treating pain such as neuropathic pain, ocular pain, chronic pain, pain resulting from chemotherapy or radiation, pain resulting from nerve injury or nerve degeneration, and pain resulting from an inflammatory condition, dysesthesia, or allodynia.
    Type: Application
    Filed: July 29, 2020
    Publication date: August 25, 2022
    Inventors: Kunwar SHAILUBHAI, Rajkumar V. PATIL
  • Patent number: 11319346
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: May 3, 2022
    Assignee: Bausch Health Ireland Limited
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Publication number: 20220119449
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Application
    Filed: August 9, 2021
    Publication date: April 21, 2022
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Publication number: 20220008533
    Abstract: This invention relates to methods of treating disorders such as celiac disease by administrating anti-CD3 antibodies alone or in combination with additional agents.
    Type: Application
    Filed: October 31, 2019
    Publication date: January 13, 2022
    Inventor: Kunwar SHAILUBHAI
  • Publication number: 20210403508
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Application
    Filed: September 17, 2021
    Publication date: December 30, 2021
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Publication number: 20210379142
    Abstract: This invention provides a method of colonic cleansing.
    Type: Application
    Filed: February 24, 2021
    Publication date: December 9, 2021
    Inventors: Dennis RIFF, Gary S. JACOB, Kunwar SHAILUBHAI, Patrick H. GRIFFIN
  • Patent number: 11142549
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: October 12, 2021
    Assignee: Bausch Health Ireland Limited
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Publication number: 20210284743
    Abstract: The present disclosure provides compositions and methods for the treatment of coronavirus infections, such as SAR-CoV, SARS-CoV-2, and MERS-CoV. The compositions include antibodies targeting the IL-6 receptor complex, antibodies targeting CD3, dactinomycin, and combinations thereof. The methods of treatment include administration of antibodies and combination therapies to reduce or eliminate symptoms associated with coronavirus infection or pulmonary inflammatory disease.
    Type: Application
    Filed: March 10, 2021
    Publication date: September 16, 2021
    Inventors: Kunwar SHAILUBHAI, Gabriele CERRONE, Vaseem A. PALEJWALA, Jules S. JACOB
  • Publication number: 20210275463
    Abstract: The disclosure provides compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (MDS) or cancer, for example, NPM1-mutated acute myeloid leukemia (AML), by administration of the compositions of the disclosure.
    Type: Application
    Filed: March 5, 2021
    Publication date: September 9, 2021
    Inventor: Kunwar SHAILUBHAI
  • Publication number: 20210205406
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: March 19, 2021
    Publication date: July 8, 2021
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Patent number: 10973773
    Abstract: The disclosure provides compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (MDS) or cancer, for example, NPM1-mutated acute myeloid leukemia (AML), by administration of the compositions of the disclosure.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 13, 2021
    Assignee: Tiziana Life Sciences PLC
    Inventor: Kunwar Shailubhai
  • Patent number: 10967043
    Abstract: This invention provides a method of colonic cleansing.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: April 6, 2021
    Assignee: Bausch Health Ireland Limited
    Inventors: Dennis Riff, Gary S. Jacob, Kunwar Shailubhai, Patrick H. Griffin
  • Publication number: 20210000957
    Abstract: This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages and dosing regimens of anti-CD3 antibodies, as well as to methods for using such formulations and dosages and dosing regimens.
    Type: Application
    Filed: May 18, 2020
    Publication date: January 7, 2021
    Applicant: Tiziana Life Sciences PLC
    Inventor: Kunwar SHAILUBHAI
  • Publication number: 20200399315
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Application
    Filed: July 6, 2020
    Publication date: December 24, 2020
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Publication number: 20200390769
    Abstract: This application relates to methods of treating and/or preventing cancer (e.g., non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma) in patients in need thereof comprising administering to the patient a therapeutically effective amount of a CDK inhibitor (e.g., milciclib) in combination with a therapeutically effective amount of another anticancer drug (e.g., sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib).
    Type: Application
    Filed: June 29, 2020
    Publication date: December 17, 2020
    Inventor: Kunwar SHAILUBHAI
  • Publication number: 20200384068
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: August 14, 2020
    Publication date: December 10, 2020
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Publication number: 20200330548
    Abstract: This invention provides a method to prevent, control, and/or treat opioid induced dysfunctions comprising administering to a patient in need a guanylate cyclase receptor agonist (GCRA) peptide. Compositions comprising guanylate cyclase receptor agonist (GCRA) peptides, methods of making, and methods of treatment are also disclosed.
    Type: Application
    Filed: May 14, 2020
    Publication date: October 22, 2020
    Inventors: Kunwar SHAILUBHAI, Vaseem PALEJWALA
  • Publication number: 20200325176
    Abstract: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis.
    Type: Application
    Filed: May 9, 2020
    Publication date: October 15, 2020
    Inventors: Kunwar Shailubhai, Gregory Nikiforovich, Gary S. Jacob